A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Almirall S.A.
Most Recent Events
- 29 Jan 2025 Planned End Date changed from 1 Jan 2025 to 1 Oct 2025.
- 29 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Oct 2025.
- 29 Jan 2024 Status changed from not yet recruiting to recruiting.